Company Overview and Recent Challenges
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company specializing in protein-based vaccines enhanced by its proprietary Matrix-M adjuvant. The company’s profile rose during the COVID-19 pandemic with its Nuvaxovid vaccine, but manufacturing setbacks and late market entry meant it captured only a low-single-digit U.S. market share in the recent vaccination campaign ([1]). After a meteoric rise early in the pandemic (peaking at over a $20 billion market value), Novavax’s shares have since plummeted over 98% from their highs ([1]). This collapse reflects the company’s past hurdles – including regulatory delays, an overly slow rollout relative to mRNA rivals, and concerns about its financial footing. However, Novavax has been undergoing a strategic turnaround: new leadership took charge in early 2023, operating costs are being slashed, and partnership deals have injected much-needed capital. The bull case for NVAX rests on the premise that the market is undervaluing the company’s stabilized finances, advanced vaccine technology, and pipeline potential now that many prior uncertainties have been addressed.
Dividend Policy & Yield
Novavax has never paid a cash dividend on its common stock, and management has no plans to initiate dividends in the foreseeable future ([2]). Any earnings or cash flow are reinvested into vaccine development rather than distributed to shareholders ([2]). As a result, NVAX’s dividend yield stands at 0%, and investors seeking income will not find it here. (Traditional REIT metrics like FFO/AFFO are not applicable to a biotech like Novavax, which does not generate steady operating cash flows or pay dividends.) This no-dividend policy is common for clinical-stage and growth biotechs, reflecting Novavax’s priority to fund R&D and product launches. Investors in NVAX are thus betting on capital appreciation rather than income – a reasonable stance given the company’s historic net losses and need to achieve sustainable profitability before any consideration of shareholder payouts.
Leverage, Debt Profile and Maturities
Leverage at Novavax is a double-edged sword: the absolute debt level is moderate, but the company’s capacity to service debt is constrained by negative cash flow. Novavax’s sole long-term debt is a $175.3 million convertible senior note due December 2027 carrying a 5.00% interest rate ([2]) ([2]). Interest on this note costs about $8.8 million per year in cash outflow. Notably, Novavax successfully extinguished a $325 million 3.75% convertible note that matured in February 2023 – it paid the entire principal at maturity ([2]). While eliminating that 2023 note removed a looming liability, it also significantly drained cash reserves at the start of 2023. The remaining 2027 notes have no principal due for another two years, which gives Novavax some breathing room on repayments. However, the company explicitly warns that operational cash flow is insufficient to service debt – “We do not expect our business to be able to generate cash flow from operations sufficient to service our debt… [and] may therefore be required to adopt alternatives such as selling assets or obtaining additional equity capital.” ([2]). This language underscores that Novavax’s interest coverage from earnings is effectively non-existent today; debt service relies on external funding and existing cash balances rather than internally generated profits.
Balance sheet context: as of year-end 2023, Novavax had total assets of ~$1.80 billion against total liabilities of ~$2.51 billion ([2]) ([2]). This imbalance resulted in a shareholders’ deficit (negative equity) of over $700 million ([2]) – a red flag in traditional leverage terms. The deficit reflects accumulated losses from prior years. Crucially, Novavax took steps in 2024 to shore up liquidity and reduce leverage. In May 2024, it announced a transformative licensing deal with Sanofi that brought in an upfront payment of $500 million plus a $70 million equity investment by Sanofi for a 4.9% stake ([3]). Then in late 2024 Novavax agreed to sell its Czech Republic manufacturing facility to Novo Nordisk for $200 million, yielding ~$190 million in immediate cash proceeds ([4]) and removing the costs of operating that plant. Management described the Novo Nordisk deal as “non-dilutive capital” to help fund its vaccine pipeline and noted it would significantly cut annual operating expenses associated with running the site ([4]). These moves – along with ongoing at-the-market stock issuances and a strategic investment by partner SK bioscience – have injected hundreds of millions in cash, easing near-term liquidity fears. In fact, by May 2024 Novavax had amassed about $481 million in cash on hand ([5]), and with the Sanofi and Novo Nordisk inflows, pro forma cash was well over $1 billion. This cash is being used to fund operations and ensure the 5% 2027 notes and other obligations can ultimately be repaid or refinanced.
NVIDIA’s Next Superchip: THOR
Secret Supplier Could Soar — See The Ticker
Small chipmaker with a 20-year contract, 6,800 patents, and the kind of upside NVIDIA partners have delivered before. Want the name? Grab the special report.
From a debt maturity standpoint, Novavax now has no major debt due until late 2027. The $175 million convertible notes mature on December 15, 2027, unless converted to equity before then ([2]). The conversion price is about $12.50 per share (80 shares per $1,000 note) ([2]) ([2]), meaning conversion is unlikely unless NVAX’s stock more than doubles from recent levels. Thus, investors should assume the full $175 million will remain on the books through 2027, accruing interest. Aside from this, the company’s other liabilities include finance leases (~$61 million) and significant deferred revenue tied to prepaid vaccine orders. The largest such obligation was an advance from Gavi, the Vaccine Alliance: Novavax originally took $700 million upfront from Gavi in 2021 to supply vaccines to low-income countries, but as deliveries fell short, most of that remained unearned. In early 2024, Novavax struck a settlement with Gavi, agreeing to repay $75 million upfront and $80 million per year from 2024 through 2028 (total $400 million), unless those amounts are offset by vaccine shipments Gavi funds each year ([6]) ([6]). In essence, Novavax has up to a $475 million liability through 2028 to Gavi, but it can “pay” it down by delivering product – an arrangement that could significantly reduce cash outlay if its vaccines (COVID-19 or others) find demand in eligible countries. This Gavi settlement removed an overhang of uncertainty (including an arbitration suit) but still represents a substantial claim on Novavax’s future cash flows ([6]) ([6]). Investors should monitor Novavax’s ability to generate sales that utilize these credits, as failure to do so means the company must make the cash payments.
Bottom line on leverage: Novavax’s debt load is manageable in size (no near-term maturities, and debt-to-assets of ~10%), especially after recent capital raises. The company has aggressively raised equity and sold non-core assets to ensure it can meet obligations. However, coverage ratios are weak – interest and deferred obligations far exceed current operating income. The bull case assumption is that Novavax’s cash buffer and new partner funding will bridge the gap until its operations turn cash-flow positive. Indeed, by May 2024 the company was confident enough to remove its “going concern” warning, citing the Sanofi deal’s cash infusion and other cost-cutting as reasons it expects to stay solvent for at least the next year ([3]). This marked a significant turning point from early 2023, when auditors raised substantial doubt about Novavax’s ability to continue as a going concern absent new funding. Now, with a bolstered balance sheet, Novavax’s financial distress has been meaningfully reduced – a core pillar of the bull thesis. Any future debt financing needs (for example, to fund expansion or repay the 2027 notes) would likely be met through additional partnerships or equity, given management’s demonstrated ability to strike strategic deals.
Valuation and Comparables
Novavax’s stock appears deeply discounted relative to its industry peers and its own assets, which is central to the bull case. After the collapse in share price, NVAX now trades at a very low multiple of its sales and book value. For 2023, Novavax reported approximately $984 million in total revenue ([1]) (mostly from COVID-19 vaccine sales and related grants). Even at an early 2024 market capitalization of under $600 million ([1]), the stock was trading at only ~0.6× that annual revenue – an extremely low price-to-sales (P/S) ratio for a vaccine developer. Even after a post-deal rebound (shares roughly doubled on the Sanofi news), Novavax’s enterprise value-to-sales remains around 1× or less on a forward basis. By comparison, larger COVID vaccine peers trade at significantly higher multiples; for instance, Moderna and Pfizer (with established franchises) command multi-billion-dollar valuations despite their COVID vaccine revenues declining, reflecting investor confidence in their broader pipelines. Novavax, with its niche yet proven technology, appears undervalued on a relative basis if it can stabilize annual revenues in the high hundreds of millions. Notably, the company raised its 2025 revenue forecast to about $1.0–$1.05 billion (from roughly $975 million) on the back of new supply partnerships ([7]). If Novavax achieves ~$1 billion in annual sales in the coming years, a 1× sales multiple looks undemanding – any improved market sentiment or revenue beat could expand that multiple closer to industry norms.
Traditional earnings-based valuation is tricky because Novavax has mostly recorded net losses. However, in one recent trailing 12-month period the company showed a slim net profit thanks to one-time milestone payments, yielding a trailing P/E ratio near 3 ([8]). This illustrates the option value in Novavax’s model: if partnerships and cost cuts can push it to sustained profitability, the stock’s earnings multiple would be extremely low. Bulls argue that even assigning modest value to Novavax’s pipeline (beyond COVID) could justify a significantly higher share price. It’s also worth noting Novavax holds valuable intangible assets: its Matrix-M adjuvant and vaccine manufacturing know-how. For example, Novavax’s adjuvant is a key component in the new R21 malaria vaccine (developed by Oxford University/Serum Institute) that won a landmark WHO endorsement in 2023 ([9]). This suggests potential royalty or supply revenue streams outside Novavax’s own sales. While such upside isn’t fully reflected in current financials, a larger player might value these assets highly in an acquisition scenario. Indeed, Novavax’s enterprise value (EV), which factors in its cash on hand, is even lower than its market cap – roughly ~$500–600 million after recent cash infusions, versus tangible assets (like cash, receivables, inventory) that approach that figure. In essence, the market is pricing Novavax as if its pipeline and technology have minimal value beyond the cash and near-term COVID sales. Bulls see this as an inefficient valuation, arguing that as Novavax executes on new products (e.g. a combined COVID-flu shot) and demonstrates a path to breakeven, the stock could rerate sharply upwards.
For a rough peer comparison: Moderna (NASDAQ: MRNA), with 2023 vaccine sales several times Novavax’s, trades at around 4–5× sales; even smaller biotechs with approved products often trade at 2–3× sales. If Novavax’s execution improves, one could argue for at least a 1.5–2× sales multiple, which on ~$1 billion of sales would imply a market cap of $1.5–$2 billion (2–3× the recent $600–$800 million range). Moreover, with partnerships shouldering much of the R&D cost going forward, Novavax’s operating leverage could increase – meaning incremental revenues might contribute more directly to the bottom line. Investors bullish on NVAX are effectively betting that the current valuation reflects overly pessimistic assumptions, and that any positive surprises (higher vaccine uptake, new product approvals, or a takeover offer) could result in substantial upside from today’s depressed share price.
Coverage and Cash Flow Considerations
(“Coverage” in this context refers to how well the company’s earnings or cash flows cover its fixed charges like interest and preferred dividends.) Given Novavax’s ongoing losses, coverage ratios are currently weak. The company does not generate positive EBITDA or operating income to cover its ~$9 million in annual interest expense. As cited earlier, management has acknowledged it must rely on external funding to meet obligations ([2]). In 2023, Novavax’s interest expense on convertibles was about $11–14 million ([2]), while its net loss for the year was roughly $545 million (indicating negative EBIT). Thus, traditional measures like interest coverage (EBIT/Interest) are not meaningful (NM) – Novavax’s earnings do not cover its interest, and the shortfall is made up by using cash on hand. However, Novavax’s recent restructuring has aimed to improve this situation by cutting expenses dramatically. The company guided that its R&D plus SG&A expenses would fall to $700–$800 million in 2024, down from over $1.2 billion in 2023 ([1]). This ~40% expense reduction means that if Novavax can hit the revenue targets ($650–$700 million forecast for 2024, revised down from $1 billion ([10])), its operating losses will shrink and move closer to covering fixed costs. Indeed, by the first half of 2025 Novavax had managed to report smaller quarterly losses and even a net income in one quarter due to a large one-time payment ([11]) ([12]). In Q2 2025, for example, Novavax received a $175 million milestone payment upon U.S. approval of its vaccine, which helped it beat earnings estimates and likely turned that quarter profitable ([11]). Such infusions show how partnership milestones can temporarily improve coverage.
Quick — Want the report emailed now?
Enter your email and we\'ll send the full guide: “Trump's Secret Fund: How to Collect Passive Income.”
No tricks — instant download after you click.
Going forward, Novavax’s interest coverage and cash-flow coverage are projected to improve if it can execute its business plan: operating costs are coming down, royalty/license income could kick in (e.g. from Sanofi sharing commercialization) and product sales from a potential combo vaccine or updated COVID shots could stabilize revenues. Until break-even is reached (currently not expected until around 2028 under management’s latest timeline ([13])), Novavax will continue to fund any cash flow deficits from its reserves. Fortunately, the company’s current cash balance (bolstered by >$500 million from Sanofi/Novo deals) provides a cushion for a few years of operations at the current burn rate. Additionally, Sanofi will be co-funding some future trials – for instance, Sanofi is covering ~70% of the costs of a planned 2025–26 post-marketing study of Nuvaxovid ([14]) ([14]) – reducing Novavax’s cash burn. In summary, while Novavax’s interest coverage is presently poor, the steps taken to reduce expenses and bring in partner funding are steadily improving the situation. The bull case assumes that Novavax can navigate the next couple of years without liquidity crises, allowing its longer-term investments to pay off. Close monitoring of quarterly cash burn, remaining cash, and any new financing will be important for investors as part of the coverage analysis.
Risks, Red Flags and Open Questions
Despite the attractive upside scenario, Novavax faces several significant risks and red flags that investors must consider:
– Weak COVID-19 Vaccine Demand: Novavax’s only marketed product is its COVID-19 vaccine, and demand for booster shots has been underwhelming. The company has repeatedly cut its 2024 revenue forecast due to lower-than-expected COVID vaccine sales ([10]) ([10]). Initially hoping for up to $1 billion in 2024 revenue, Novavax by late 2024 guided only $650–$700 million ([10]). U.S. sales, in particular, have been minimal – the CEO admitted U.S. 2023–24 season sales were below $25 million (a tiny fraction of the market) ([1]). This raises concern about whether Novavax’s vaccine can compete against dominant players Pfizer/BioNTech and Moderna. If COVID product revenues continue to dwindle (or if new strain-specific boosters fail to gain traction), Novavax may not reach profitability on its current product line. The bull case assumes that either COVID vaccine uptake improves (possibly if Novavax captures the market segment that prefers a traditional protein vaccine over mRNA) or that new products like the COVID–influenza combo will rejuvenate sales. This remains an open question – recent trends suggest baseline COVID vaccine demand is much lower post-pandemic, so Novavax is essentially betting on differentiating its product or combining it with flu to create a new value proposition.
– Path to Profitability and Cash Burn: Novavax does not expect to be profitable until at least 2028 ([13]), a year later than prior targets. This delay in the breakeven timeline was announced in late 2025 as the company acknowledged it needs more time and new product launches (like the Sanofi-partnered combo vaccine) to reach sustainable profits ([13]). The risk is that Novavax will continue to burn cash for several more years, eroding its cash cushion. Any cost overruns, clinical trial failures, or further revenue shortfalls could force Novavax to dilute shareholders with additional equity raises or take on expensive debt. The company has already more than doubled its share count in recent years (from ~48 million in 2020 to ~140 million by the end of 2023 ([2])) through stock offerings to fund operations. While the infusion of partner capital in 2024 reduced near-term pressure, investors face ongoing dilution risk if Novavax cannot self-fund by the time the Sanofi milestone payments wind down. Additionally, a significant portion of Novavax’s assets is tied up in inventory and prepaid expenses; if some of this inventory (e.g. vaccine stockpiles) becomes obsolete due to variant changes or lack of demand, there could be write-downs that further hit the balance sheet. In short, the execution risk over the next 2–3 years is high: Novavax must carefully manage its spending and hit its product launch timelines to avoid another cash crunch.
– Concentrated Product Portfolio: All of Novavax’s revenue today comes from one product – its COVID-19 vaccine. This concentration is a classic red flag. Any safety issues, regulatory setbacks, or further decline in public uptake for that vaccine would leave Novavax with little to fall back on. The company is attempting to broaden its portfolio with a combined COVID-19/influenza vaccine and a standalone nanoparticle flu vaccine in development. Promisingly, in mid-2025 a Phase 2 trial showed that Novavax’s experimental COVID–flu combo shot generated strong immune responses in older adults, comparable to stand-alone vaccines ([14]). The combo and flu-only shots were also well tolerated, with no new safety concerns reported ([14]). However, that trial was not designed to prove efficacy; a larger Phase 3 trial will be needed before regulatory approval ([14]). It’s an open question whether Novavax (and partner Sanofi) can swiftly bring the combo vaccine to market and capture a meaningful share of the seasonal vaccine market. They face competition from mRNA combo vaccines (Moderna is developing one) and established flu shot manufacturers. If these pipeline candidates falter or take too long, Novavax’s reliance on the aging COVID vaccine could become an existential problem. On the flip side, successful approval of the combo shot by, say, 2026–27 could be a game-changer that validates Novavax’s platform and provides a multi-product revenue base – a key element of the bull case, but one that is not guaranteed.
– Regulatory and Manufacturing Hurdles: Novavax has a history of regulatory delays. The FDA only granted full approval to Nuvaxovid in mid-2023/early-2025 (after missing an earlier deadline) and even then with conditions limiting its use to certain populations ([14]). While approval in the U.S. is a positive, the label restriction (for adults 65+ and at-risk younger individuals) could limit market size ([14]). This raises the risk that any new Novavax vaccines might also face protracted reviews or cautious labeling, especially given heightened safety scrutiny on combination vaccines. Manufacturing is another factor – Novavax’s manufacturing network had issues ramping up in 2021–2022. The company has since streamlined operations (e.g. exiting its Czech plant) and leaned on partners like the Serum Institute of India. Nonetheless, ensuring high-quality production for new vaccines (especially a combo shot) is critical. Any manufacturing snafus or supply chain problems could derail product launches or result in missed delivery obligations (as happened with the Gavi contract, now settled). Investors should watch for updates on production readiness for the next-gen vaccines; the bull thesis assumes those will roll out smoothly with Sanofi’s help, but it remains an area of execution risk.
– Shareholder Activism and Governance: A recent development is that an activist investor, Shah Capital (holder of ~7% of NVAX), has begun agitating for change. In late 2025, Shah Capital sent letters to Novavax’s board urging them to pursue strategic alternatives including a possible sale of the company, citing frustration with management missteps and the stock’s persistent underperformance ([15]). Shah Capital pointed out that despite Novavax’s valuable technology, the company has failed to deliver value to shareholders and might be worth more in the hands of a larger pharmaceutical owner ([15]). While this activism signals that major shareholders see the status quo as unsatisfactory (a red flag on governance and execution), it also introduces the possibility of M&A. If Novavax’s board seriously explores a sale, it could unlock value; indeed, even rumors of buyout interest can boost a stock. However, there is no guarantee of a buyer, and management has so far focused on independent operation. Investors should be aware that continued underperformance could lead to a proxy fight or leadership changes – Shah Capital has hinted at that path if results don’t improve ([16]) ([13]). Such uncertainty can add near-term volatility. The bull case does not hinge on an imminent sale, but the prospect of one provides a kind of valuation backstop: with NVAX’s market cap so low, it could be a tempting target for acquisition (for example, a big pharma might pay a premium to acquire Novavax’s vaccine platform and adjuvant technology). This dynamic is a double-edged sword – it could surface value, but it also underscores that current management has struggled to earn investor confidence.
– Other Red Flags: Novavax underwent a major workforce reduction in 2023 (cutting ~25–50% of staff) as part of its restructuring ([2]). While necessary for cost savings, this could have longer-term impacts such as loss of institutional knowledge or overburdening the remaining team. The company itself acknowledged that turnover in key positions and layoffs increased the risk of “losing technical know-how or trade secrets as experienced personnel depart” ([2]). Talent retention and recruitment will be crucial as Novavax pivots to a slimmer, partnership-driven model. Another concern is the overall competitive landscape for vaccines: mRNA technology has proven its speed and efficacy, and companies like Moderna and Pfizer are well-funded to dominate new vaccine markets (e.g. cancer vaccines, new infectious diseases). Novavax will need to find a niche or demonstrate superior products to stay relevant. Finally, macro factors such as the political climate around vaccines could pose risks – for instance, changes in public health policy, global vaccine funding, or vaccine hesitancy trends could affect Novavax’s sales (the Reuters piece even noted the potential impact of vaccine skeptic rhetoric on booster uptake ([14])).
Open questions that remain for the NVAX bull case include: Can Novavax successfully execute its partnership with Sanofi – i.e. will the collaboration deliver the promised milestones and product launches on time? The Sanofi deal is co-exclusive, meaning both companies need to coordinate; Sanofi’s enthusiasm and commitment will be pivotal. Another question is how significant the Matrix-M adjuvant opportunity is outside of Novavax’s own products. The adoption of Matrix-M in the R21 malaria vaccine (being rolled out in Africa in 2024 ([17])) could hint at a broader platform value. If Novavax can monetize Matrix-M via licensing to other vaccine developers (for malaria, RSV, or even veterinary vaccines), it could create a new revenue stream with minimal expense – but details on such royalties are scant. Additionally, will Novavax expand into new indications? The pipeline includes early research on combined respiratory vaccines and potentially other infectious diseases (Novavax has mentioned exploratory work in areas like tuberculosis and even partnered COVID/flu programs with different formats ([9])). If any of these materialize into clinical programs, they could diversify the company’s prospects; if not, Novavax remains a one-trick pony for longer. Lastly, from an investor standpoint, what is Novavax’s endgame? Will it remain independent through 2028 to see its profitability goal, or will the pressure from activists and partners eventually steer it into a merger or sale? The answer could significantly affect the risk/reward profile – a buyout might bring a quicker payoff at a moderate premium, whereas independent success could yield a multi-bagger if all goes well (but comes with higher risk of failure).
Conclusion
In summary, Novavax’s bull case hinges on a compelling turnaround narrative: The company has resolved its near-term survival concerns by bringing in strong partners (Sanofi, SK, Serum/Novo Nordisk) and capital, all while maintaining a promising vaccine technology platform. Novavax now enjoys a much-improved liquidity position and has a clear runway to develop next-generation vaccine products. The stock’s valuation appears washed-out, pricing in a lot of bad news and little of the good – it trades at only a fraction of sales and a tiny fraction of the value it briefly held at the pandemic’s height ([1]). For investors willing to shoulder the risk, NVAX offers optionality: success in its combo vaccine or other pipeline efforts could drive substantial upside, and even a strategic acquisition is on the table if management cannot fully capitalize on its assets.
That said, Novavax is not without significant risks. The company must execute nearly flawlessly in an unpredictable environment – vaccine demand is uncertain, competitors are formidable, and the clock is ticking on reaching profitability before cash runs low. The recent moves (cost cuts, deals, focus on core programs) are encouraging, but Novavax will need to prove it can generate consistent revenue growth beyond COVID boosters. In the quarters ahead, key indicators for the bull thesis will be: successful regulatory progress on the COVID–flu combo shot (entering Phase 3 trials and maintaining efficacy), steady improvement in operating losses (hitting or beating the reduced expense targets), and evidence that sales stabilizing (perhaps through new international orders or better uptake among specific populations). If Novavax can check those boxes, market sentiment could swiftly change. The stock that Wall Street left for dead might earn a second look as a recovery story in biotech. In conclusion, “don’t miss out” means that at today’s depressed prices, NVAX offers asymmetric upside – a chance to participate in a potential turnaround where the groundwork (financial and strategic) has been laid, even as the broader market hasn’t yet recognized the company’s improving fundamentals. As always, this opportunity must be balanced against the very real possibility that things may not go according to plan. For now, however, Novavax’s bulls have tangible reasons for optimism, grounded in the company’s concrete actions and authoritative disclosures over the past year. The next chapters for NVAX will determine if this restructuring was the prelude to a remarkable comeback in the biotech arena.
Sources: First-party filings and financial reports (SEC Form 10-K, 10-Q) and press releases were used for factual data on Novavax’s financials, debts, and corporate actions. Key insights and quotes were drawn from company statements and reputable financial media, including Reuters, Bloomberg, and company press releases, as cited throughout the report. All inline citations above reference the source material substantiating the statements made.
Sources
- https://investing.com/news/stock-market-news/novavax-says-still-faces-strong-headwinds-2024-sales-flat-to-lower-3318533
- https://sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231.htm
- https://ir.novavax.com/press-releases/2024-05-10-Novavax-Reports-First-Quarter-2024-Financial-Results-and-Operational-Highlights
- https://fiercepharma.com/pharma/novavax-scores-200m-it-hands-over-keys-czech-production-plant-along-300-employees-novo
- https://sec.gov/Archives/edgar/data/1000694/000100069424000031/nvax-20240331.htm
- https://sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231.htm
- https://reuters.com/business/healthcare-pharmaceuticals/novavax-raises-annual-revenue-forecast-vaccine-supply-partnerships-2025-08-06/
- https://accountable.finance/stock/NVAX
- https://ir.novavax.com/press-releases/R21-Matrix-M-TM-Malaria-Vaccine-with-Novavaxs-Adjuvant-Technology-Receives-WHO-Recommendation
- https://investing.com/news/stock-market-news/novavax-cuts-2024-revenue-forecast-again-on-lower-covid-vaccine-sales-3716377
- https://reuters.com/business/healthcare-pharmaceuticals/novavax-beats-quarterly-revenue-estimates-milestone-payment-2025-08-06/
- https://reuters.com/business/healthcare-pharmaceuticals/novavaxs-quarterly-loss-shrinks-it-ramps-down-spending-covid-vaccines-2025-02-27/
- https://reuters.com/business/healthcare-pharmaceuticals/novavax-beats-quarterly-revenue-estimates-milestone-payment-2025-11-06/
- https://investing.com/news/stock-market-news/novavaxs-covidflu-combo-and-standalone-flu-shots-improve-immunity-in-latestage-study-4090634
- https://reuters.com/business/healthcare-pharmaceuticals/shah-capital-pushes-novavaxs-sale-persistent-underperformance-marketing-missteps-2025-10-14/
- https://reuters.com/legal/transactional/shah-capital-pushes-novavax-sale-warns-proxy-fight-2025-11-12/
- https://ir.novavax.com/press-releases/First-Doses-of-R21-Matrix-M-TM-Malaria-Vaccine-Shipped-to-Africa
For informational purposes only; not investment advice.
